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ABSTRACT: Recently regulators of G protein signalling (RGS) proteins have emerged as potential therapeutic targets since they pro-
vide an alternative method of modulating the activity of GPCRs, the target of so many drugs. Inhibitors of RGS proteins must block a 
protein-protein interaction (RGS-Gα), but also be cell and, depending on the therapeutic target, blood brain barrier permeable.  A 
lead compound (1a) was identified as an inhibitor of RGS4 in a screening assay and this has now been optimised for activity, selectivi-
ty and solubility. The newly developed ligands (11b, 13) display substantial selectivity over the closely related RGS8 protein, lack the 
off-target calcium mobilisation activity of the lead 1a and have excellent aqueous solubility.  They are currently being evaluated in vivo 
in rodent models of depression. 
G protein-coupled receptors (GPCRs) are widely distributed through-
out the body and are an important class of therapeutic targets for drug 
discovery.1 The majority of GPCR-targeted drugs act as orthosteric ago-
nists or antagonists at the canonical ligand binding site, but recent atten-
tion has focused on drugs acting allosterically to modulate receptor activ-
ity.2 One advantage of allosteric agents is their ability to modulate ongo-
ing physiological signalling. Other approaches to modulate GPCR-
mediated signal transduction may also provide significant therapeutic 
benefit. To this end, we have focused upon targeting a class of proteins 
that negatively regulates GPCR signalling.  
Regulators of G protein signalling (RGS) proteins are potent negative 
modulators of GPCR signalling. They accelerate the rate of GTP hydrol-
ysis by G subunits of heterotrimeric G proteins, shortening the dura-
tion and decreasing the magnitude of signal after receptor activation.3  
The important role of RGS proteins in GPCR signalling has generated, 
in recent years, significant interest in RGS proteins as therapeutic targets 
in their own right.4,5  One of the attractions is that while many receptors 
are expressed throughout the body, modulators of the signalling path-
way, including RGS proteins, are expressed in a more tissue-specific 
manner.  This may be of particular importance for the development of 
centrally acting agonist therapeutics.  Of over 20 mammalian RGS pro-
teins identified, RGS4 is one of the most extensively characterised.  It is 
broadly, but heterogeneously, expressed in the central nervous system 
(CNS),6,7 less so in peripheral tissues, and has been shown to modulate 
activity of the mu opioid (MOP), delta opioid (DOP) and M3 muscarinic 
receptors amongst others.8,9 The selectivity in regional distribution, cou-
pled with the finding that RGS4 can selectively suppress signalling 
through DOP receptors compared to MOP receptors,10 suggests a level of 
specificity for RGS4 inhibitory action will be possible.     
The RGS-Gα site is a large, relatively featureless protein-protein interac-
tion (PPI) interface.11 Inhibitors of RGS proteins must act by disrupting 
this interaction either directly or through an allosteric mechanism. 
Whilst a number of PPI inhibitors are known against a variety of targets, 
most of these compounds are large molecules which lack access to the 
CNS.5  The development of cell and blood-brain barrier permeable small 
molecules that can act as selective PPI inhibitors is a non-trivial task, but 
one that could ultimately provide significant clinical benefit. 
Our group recently discovered small molecule inhibitors of RGS412-15 
using a high throughput flow cytometry protein interaction assay 
(FCPIA).16 As part of this screening process, CCG-50014 (1a, Figure 1) 
was identified as a selective inhibitor of RGS4 that acted by forming a 
covalent adduct to cysteine residues in the RGS protein.15,17  With an 
IC50 of 30 nM, it is the most potent RGS inhibitor reported to date.  In 
an attempt to further define the structural requirements for high poten-
cy inhibition of this protein, analogues of 1a have been synthesised with 
variation in both the N2 and N4 side chains.  In addition, a set of these 
newly synthesised RGS4 inhibitors have been evaluated for their effects 
on calcium mobilisation, an off-target activity displayed by 1a. 
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Figure 1: Structure and activity of lead compound, CCG50014 
The synthesis of CCG-50014 (1a) and its thiadiazolidinone (TDZD) 
analogues is shown in Scheme 1.  Commercially available isothiocya-
nates were reacted with isocyanates in the presence of sulfuryl chloride 
(Scheme 1).18 This allowed a range of R1 and R2 substituents, having 
varying lipophilic, electronic and steric properties, to be evaluated. 
While chlorine gas19 or N-chlorosuccinimide20  are also used in literature 
procedures for making TDZDs, we found the use of sulfuryl chloride 
straightforward and consistent. The resulting S-chloroisothiocarbamoyl 
chloride, proposed by Slomczyńska and Barany,18 was subsequently oxi-
dised in atmospheric oxygen to the desired products. This reaction was 
easily carried out in parallel, with typically 11 different reactions running 
 simultaneously. In total 75 TDZD analogues were synthesised, with 39 
(1a-i, 2a-i, 3-8, 9a,b, 10a-d, 11a-d, 12a-d, 13) reported in Table 1. Data 
for all compounds is reported in the supplementary information. 
 
Scheme 1: Synthesis of CCG50014 and analogues 
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Conditions: i. SO2Cl2, THF, 0 °C – rt, 18 h ii. air, 30 min 
In addition to the large series of TDZD compounds synthesised, an im-
idazolidine-2,4-dione (14)  and a maleimide (15) were both prepared to 
compare their activity to the TDZDs. Synthesis of 14 was carried out in 
three steps, starting from ethyl bromoacetate and p-toluidine (Scheme 
2a). After reaction in the presence of sodium acetate, the resulting ami-
no acetate 16 was stirred at reflux in the presence of p-methylbenzyl iso-
cyanate to provide the corresponding ureido acetate 17. This was cy-
clised using sodium hydride, providing 14. Compound 15 was synthe-
sised by first reacting bromomaleic anhydride with benzyl amine in the 
presence of acetic acid. The desired product resulted from a Suzuki reac-
tion coupling p-tolyl boronic acid to 18. 
 
Scheme 2: Synthesis of the non-TDZD analogues 
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Conditions: i. NaOAc, EtOH, 80 °C, 1 h ii. methyl benzyl isocyanate, 
toluene, reflux, 5 h iii. NaH, THF, 0 °C – rt, 18 h iv. benzylamine, AcOH, 
50 °C, 18 h v. p-tolylboronic acid, CsF, Cl2Pd(dppf).CH2Cl2, dioxane, 40 °C, 
1 h 
All compounds were evaluated using the FCPIA assay as a primary 
screen to determine IC50 values for inhibition of Go binding to both 
RGS4 and RGS8 (the closest relative to RGS4 based upon sequence 
homology).  In preliminary studies, 1a was also found to suppress Ca++ 
responses to GPCRs in a manner unrelated to its activity at RGS pro-
teins.  The most interesting of the new ligands were also assessed for this 
off-target effect. 
Table 1:  Inhibition of Go binding to RGS4 and RGS8 
 R1 R2 RGS4a RGS8a Selectivity 
   
IC50 (nM) 
IC50 
(M) 
RGS4/ 
RGS8 
1a 4-FBn 4-MePh 30.1 11.0 366 
1b 4-FBn Ph 16.3 6.20 380 
1c 4-FBn 4-ClPh 13.5 7.60 564 
1d 4-FBn 4-MeOPh 10.9 11.4 1050 
1e 4-FBn 3,4-diClPh 35.7 17.2 481 
1f 4-FBn 3-CF3Ph 79.3 16.2 204 
1g 4-FBn 3-MePh 121 7.10 59 
1h 4-FBn 3-ClPh 52.3 12.8 245 
1i 4-FBn 4-MeBn 12.9 39.8 3090 
2a Bn 4-MePh 14.4 7.5 519 
2b Bn Ph 23.5 5.60 239 
2c Bn 4-ClPh 28.7 5.20 183 
2d Bn 4-MeOPh 23.9 12.3 515 
2e Bn 3,4-diClPh 88.9 13.2 149 
2f Bn 3-CF3Ph 57.4 16.4 286 
2g Bn 3-MePh 38.2 21.3 558 
2h Bn 3-ClPh 32.5 10.9 335 
2i Bn 4-MeBn 7.20 20.4 2840 
3 4-ClBn 4-MePh 5.40 11.8 2170 
4 4-MeBn 4-MePh 8.60 11.6 1340 
5 3-ClBn 4-MePh 17.4 17.5 1005 
6 3-MeBn 4-MePh 14.5 9.90 679 
7 4-MeOBn 4-MePh 176 311.6 1780 
8 3,4-diClBn 4-MePh 34.2 15.7 460 
9a 4-FBn n-Bu 15.6 31.6 2020 
9b 4-FBn Et 22.3 18.7 842 
10a Me 4-MePh 18.9 8.40 445 
10b Me Et 22.3 37.0 1660 
10c Me n-Bu 23.5 28.4 1210 
10d Me t-Bu 27.8 56.0 2020 
11a n-Bu 4-MePh 19.7 9.50 483 
11b n-Bu Et 14.4 83.5 5810 
11c n-Bu n-Bu 29.8 122 4110 
11d n-Bu t-Bu 53.6 119 2220 
12a i-Bu 4-MePh 14.0 7.70 550 
12b i-Bu Et 26.3 70.6 2680 
12c i-Bu n-Bu 38.6 98.0 2540 
12d i-Bu t-Bu 29.1 194 6660 
13 MeOCH2CH2 Et 54.3 36.1 665 
14 4-MeBn* 4-MePh* >100000 >100 N/A 
15 Bn** 4-MePh** 93300 0.0 0 
aValues are an average from two independent experiments. The calculated 
∆pIC50 gave a mean error of 0.2 for RGS4 and 0.14 for RGS8.  * Scheme 2 
for structure of 14  ** Scheme 3 for structure of 15 
CCG-50014 (1a) was confirmed as a potent inhibitor of RGS4 with 
excellent selectivity over RGS8.  Retaining the 4-fluorobenzyl R1-group 
and varying R2 led to both more (e.g. 1d) and less (e.g. 1g) potent and 
selective compounds.  It appeared that a 3-substituent on the R2 aryl ring 
was associated with reduced RGS4 potency compared to unsubstituted 
and 4-substituted analogues (e.g. 1f, 1g, 1h cf. 1b, 1c, 1d).  While not 
completely consistent, this trend is repeated across a number of the se-
ries where R1 is held constant and R2 is varied.  A 3,4-dichlorophenyl 
group as R2 generally resulted in low potency at RGS4, and relatively low 
 selectivity (e.g. 1e, 2e). In contrast, a 4-methyl substituent was more often 
associated with high affinity and high selectivity at RGS4, with a number 
displaying >1000-fold selectivity versus RGS8 (e.g. 3, 4, 5, 7). Replace-
ment of the phenyl group by benzyl at R2 (1i, 2i) did not improve activity 
at RGS4, but did reduce RGS8 activity, resulting in each compound 
having near three orders of magnitude selectivity.  In fact, of the com-
pounds discussed so far, i.e. retaining a benzyl or substituted benzyl at 
R1, 1i and 2i were the most selective. 
Variation in the aryl groups of R1 and R2 has therefore led to the discov-
ery of a number of ligands with high potency and excellent selectivity.  
However, the uniformly high lipophilicity (ClogP typically > 4) of these 
ligands resulted in only moderate solubility in aqueous solution and they 
were therefore less than ideal for consideration for more in-depth study.  
To address this problem, analogues in which one or both R groups were 
replaced with short alkyl chains were prepared.  In the former series, 
where one aryl group was replaced by alkyl (9a,b, 10a, 11a, 12a), potency 
and selectivity at RGS4 was retained.  Making both R groups short alkyl 
chains (10b-d, 11b-d, 12b-d) substantially improved solubility (complete 
solubility at 500 µM) whilst also providing the most consistently selective 
group of compounds yet developed (all >1000-fold selective). The poten-
cy at RGS4 (IC50 14.4 nM), near 6000-fold selectivity and high solubility 
of 11b means that it is an ideal candidate for further evaluation, includ-
ing in vivo studies. As a means to even further enhance solubility of this 
compound, analogues containing ether side chains were considered and 
the ether analogue of 11b prepared.  This compound (13) retained good 
potency (56 nM) and excellent selectivity (>600-fold).  
The effect of 1a, 11b, and 13 were tested on the Ca2+ transient induced 
by M3 muscarinic receptors in HEK293T cells. 1a at 10 µM nearly com-
pletely abolished the carbachol-induced Ca2+ transient (Figure 2) while 
11b and 13 had no effect. The action of 1a on this response cannot be 
through effects on RGS proteins since HEK cells express minimal levels 
of functional RGS proteins.21  
We have previously published our studies which indicate that the lead 
compound (1a) reacts to form an adduct with a cysteine residue on the 
RGS protein through disulfide bond formation.15 The proposed mecha-
nism (Scheme 3, 19b) is analogous to that proposed by Nasim and 
Crooks for the ring-opening of TDZDs with PPh3.
20  To help confirm the 
importance of disulfide bond formation to the activity of this series of 
ligands, analogues 14 and 15 were prepared. Compound 14 is the imid-
azolidine-2,4-dione analogue of 4, while 15 is the maleimide analogue of 
2i; 4 and 2i being two of the most potent inhibitors discovered.  As ex-
pected, neither 14 or 15 displayed activity at RGS4.  Also supporting the 
disulfide bond forming mechanism, the reaction of propane thiol with 
1a appears to give efficiently and cleanly the expected adduct 19a, 
(Scheme 3). Importantly, 1a is not a general cysteine alkylator, failing to 
inhibit the cysteine protease papain, suggesting selectivity for RGS4.15 
 
Figure 2: Effect of compounds on carbachol-simulated Ca++ responses. 
HEK-293 cells stably transfected with the human M3 muscarinic receptor 
were plated in black, clear-bottomed, 96-well  plates overnight. They were 
loaded with Fluo4-NW according to the manufacturer’s instructions. After 
30 minutes of loading at 37 °C, the indicated compounds were added at a 
concentration of 10 uM (with 1% DMSO). After 30-45 minutes, the base-
line fluorescence was measured in a Flex-3 plate reader (Molecular Devices). 
Then carbachol (10 nM final) was injected into the wells and the increase in 
intracellular Ca++ was measured and is expressed as the percentage of the 
baseline Ca++ level. Values are the mean ± SD of triplicate determinations 
(compounds) and 16 determinations (DMSO). 
Scheme 3: Proposed mechanism of reaction of a thiol with 1a  
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Previously thiadiazolidine-3,5-diones have been reported as having a 
number of biological effects,22-24 including being glycogen synthase kinase 
3 (GSK-3) inhibitors with activities in the M range.19  This latter 
activity has been suggested to account, at least in part, for the antidepres-
sant–like effects in mice of the TDZD NP031115.25  Interestingly, 11b 
was evaluated as part of that study and was found to be one of the weak-
er inhibitors (GSK-3 IC50 70 M) meaning that it has significant selec-
tivity (almost 5000-fold) for RGS4 over GSK-3.  As such, 11b should 
prove to be an invaluable tool in defining the physiological role of RGS4 
in vivo, including a potential role in 5-HT1A-mediated antidepressant 
effects.26   
In summary, a series of RGS4 inhibitors has been synthesised with im-
proved selectivity over RGS8 and lacking the off-target calcium mobilisa-
tion activity of the lead 1a.  One compound, 11b combines potency 
(RGS4 IC50 14 nM) and selectivity (5800-fold over RGS8 and no calci-
um transient) with excellent aqueous solubility and should prove an 
invaluable tool for better defining the role of RGS4 and its potential as a 
therapeutic target.  Its ether analogue (13) had further improved solubili-
ty whilst retaining good potency and selectivity. Analogues 11b and 13 
are now being evaluated in vivo with positive preliminary data and the 
results of this latter work will be reported separately. 
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